Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal amino acids: a therapy whose time has come?

M R Jones1

  • 1Renal Division, Baxter Healthcare Corporation, McGaw Park, Illinois 60085-6730, USA.

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 5869.

International journal of molecular sciences·2024
Same author

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.

International journal of molecular sciences·2023
Same author

Whole-genome and transcriptome analysis enhances precision cancer treatment options.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Letter to the Editor: Frailty Status and Outcomes of COVID-19 Patients Admitted to an Intensive Care Unit.

The Journal of frailty & aging·2022
Same author

Antagonistic Effects of Point Mutations on Charge Recombination and a New View of Primary Charge Separation in Photosynthetic Proteins.

The journal of physical chemistry. B·2021
Same author

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Intradialytic parenteral nutrition (IDPN) is currently feasible but costly and limited. A specialized amino acid dialysis solution for intradialytic parenteral nutrition (IPAA) is available in Europe, potentially improving nutritional status for dialysis patients.

Area of Science:

  • Nephrology
  • Nutritional Science
  • Internal Medicine

Background:

  • Maintaining adequate nutritional status in patients undergoing peritoneal dialysis (PD) is crucial for their overall health and treatment outcomes.
  • Intradialytic parenteral nutrition (IDPN) has been explored as a method to supplement nutrition during dialysis sessions.
  • The efficacy and accessibility of specific nutritional therapies for PD patients remain areas of active investigation.

Purpose of the Study:

  • To evaluate the current feasibility, cost-effectiveness, and benefits of intradialytic parenteral nutrition (IPN) for patients on peritoneal dialysis (PD).
  • To assess the availability and potential impact of a 1.1% amino acid dialysis solution for intradialytic parenteral nutrition (IPAA) therapy.

Main Methods:

  • This review synthesizes existing data and clinical experience regarding the use of IPN and IPAA in PD patients.

Related Experiment Videos

  • Analysis includes current limitations, cost considerations, and reported benefits of these nutritional interventions.

    • Main Results:

    • Intradialytic parenteral nutrition (IPN) is currently possible but faces limitations in terms of cost and uncertain benefits.
    • A 1.1% amino acid dialysis solution for IPAA therapy is available in Europe but lacks US approval.
    • Wider availability of IPAA could enhance its role in nutritional management for PD patients.

    Conclusions:

    • Intradialytic parenteral nutrition (IPN) offers a potential, albeit currently limited and expensive, method for nutritional support in PD patients.
    • The availability of specialized amino acid solutions like IPAA is expected to improve nutritional maintenance in PD.
    • IPAA holds promise as an adjunctive therapy for optimizing nutritional status in the context of peritoneal dialysis.